• Je něco špatně v tomto záznamu ?

Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial

DS. Moura, JM. Lopez-Marti, I. Benesova, C. de Andrea, D. di Lernia, S. Lacerenza, JL. Mondaza-Hernandez, M. Martin-Ruiz, M. Ramirez-Calvo, G. Grignani, J. Martinez-Trufero, A. Redondo, C. Valverde, S. Stacchiotti, A. Lopez-Pousa, JA....

. 2024 ; 30 (22) : 5192-5206. [pub] 20241115

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003456

Grantová podpora
Sarcoma Foundation of America (SFA)
NA Asociacion Iker
GEIS-52 Spanish group for research on Sarcoma
GA UK No. 94323 Charles University
AZV NU23J-08-00031 Ministry of Health, Czech Republic
825806 Horizon 2020 Framework Programme (H2020)
CD20/00155 Instituto de Salud Carlos III (ISCIII)

PURPOSE: The IMMUNOSARC trial combined an antiangiogenic agent (sunitinib) with a PD1 inhibitor (nivolumab) in advanced sarcomas. Here, we present the first correlative studies of the soft-tissue sarcoma cohort enrolled in this trial. EXPERIMENTAL DESIGN: Formalin-fixed paraffin-embedded and peripheral blood samples were collected at baseline and week 13. Formalin-fixed paraffin-embedded samples were used for transcriptomics and multiplex immunofluorescence, whereas peripheral blood samples were used for multiplexed immunoassays. Flow cytometry and Luminex assays were performed to validate translational findings in tumor-isolated cells and peripheral blood mononuclear cells derived from patients. RESULTS: The density of intratumoral CD8+ T cells, measured by multiplexed immunophenotyping, was significantly increased after treatment. This augment was accompanied by the dynamic significant increase in the gene expressions of CD86, CHI3L1, CXCL10, CXCL9, LAG3, and VCAM1 and the decrease in the expression levels of NR4A1. In peripheral blood, 12 proteins were significantly modulated by treatment at week 13. A score integrating the dynamic expression of the 7 genes and the 12 soluble factors separated 2 groups with distinct progression-free survival (PFS): 4.1 months [95% confidence interval, 3.5-not reached (NR)] versus 17 months (95% confidence interval, 12.0-NR), P = 0.014. This molecular score was predictive of PFS when applied to the normalized data determined in the baseline samples. CONCLUSIONS: Treatment with sunitinib and nivolumab inflamed the sarcoma microenvironment, increasing CD8+ T-cell density and the expression of several genes/proteins with relevance in the response to PD1 inhibitors. A molecular signature identified two groups of patients with distinct PFS for the combination of antiangiogenics plus PD1 inhibitor therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003456
003      
CZ-PrNML
005      
20250206104343.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1078-0432.CCR-24-1782 $2 doi
035    __
$a (PubMed)39283727
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Moura, David S $u Research Health Institute of Fundacion Jimenez Diaz (IIS/FJD; UAM), Madrid, Spain $1 https://orcid.org/0000000265142419
245    10
$a Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial / $c DS. Moura, JM. Lopez-Marti, I. Benesova, C. de Andrea, D. di Lernia, S. Lacerenza, JL. Mondaza-Hernandez, M. Martin-Ruiz, M. Ramirez-Calvo, G. Grignani, J. Martinez-Trufero, A. Redondo, C. Valverde, S. Stacchiotti, A. Lopez-Pousa, JA. Lopez-Guerrero, A. Gutierrez, V. Encinas-Tobajas, N. Hindi, D. Sangiolo, JA. Lopez-Martin, ZO. Strizova, J. Martin-Broto
520    9_
$a PURPOSE: The IMMUNOSARC trial combined an antiangiogenic agent (sunitinib) with a PD1 inhibitor (nivolumab) in advanced sarcomas. Here, we present the first correlative studies of the soft-tissue sarcoma cohort enrolled in this trial. EXPERIMENTAL DESIGN: Formalin-fixed paraffin-embedded and peripheral blood samples were collected at baseline and week 13. Formalin-fixed paraffin-embedded samples were used for transcriptomics and multiplex immunofluorescence, whereas peripheral blood samples were used for multiplexed immunoassays. Flow cytometry and Luminex assays were performed to validate translational findings in tumor-isolated cells and peripheral blood mononuclear cells derived from patients. RESULTS: The density of intratumoral CD8+ T cells, measured by multiplexed immunophenotyping, was significantly increased after treatment. This augment was accompanied by the dynamic significant increase in the gene expressions of CD86, CHI3L1, CXCL10, CXCL9, LAG3, and VCAM1 and the decrease in the expression levels of NR4A1. In peripheral blood, 12 proteins were significantly modulated by treatment at week 13. A score integrating the dynamic expression of the 7 genes and the 12 soluble factors separated 2 groups with distinct progression-free survival (PFS): 4.1 months [95% confidence interval, 3.5-not reached (NR)] versus 17 months (95% confidence interval, 12.0-NR), P = 0.014. This molecular score was predictive of PFS when applied to the normalized data determined in the baseline samples. CONCLUSIONS: Treatment with sunitinib and nivolumab inflamed the sarcoma microenvironment, increasing CD8+ T-cell density and the expression of several genes/proteins with relevance in the response to PD1 inhibitors. A molecular signature identified two groups of patients with distinct PFS for the combination of antiangiogenics plus PD1 inhibitor therapy.
650    _2
$a lidé $7 D006801
650    12
$a sarkom $x farmakoterapie $x patologie $x genetika $7 D012509
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a inhibitory angiogeneze $x terapeutické užití $x aplikace a dávkování $7 D020533
650    _2
$a lidé středního věku $7 D008875
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a inhibitory kontrolních bodů $x terapeutické užití $x farmakologie $7 D000082082
650    _2
$a antigeny CD279 $x antagonisté a inhibitory $7 D061026
650    _2
$a nivolumab $x terapeutické užití $x aplikace a dávkování $7 D000077594
650    _2
$a CD8-pozitivní T-lymfocyty $x imunologie $x účinky léků $x metabolismus $7 D018414
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a tumor infiltrující lymfocyty $x imunologie $x metabolismus $x účinky léků $7 D016246
650    _2
$a nádorové biomarkery $7 D014408
650    _2
$a nádorové mikroprostředí $x účinky léků $x imunologie $7 D059016
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lopez-Marti, Jesus M $u Research Health Institute of Fundacion Jimenez Diaz (IIS/FJD; UAM), Madrid, Spain $1 https://orcid.org/0000000230061360
700    1_
$a Benesova, Iva $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000348864214
700    1_
$a de Andrea, Carlos $u Department of Pathology, Clinica Universidad de Navarra, Pamplona, Spain $1 https://orcid.org/0000000276288050
700    1_
$a di Lernia, Davide $u Research Health Institute of Fundacion Jimenez Diaz (IIS/FJD; UAM), Madrid, Spain $1 https://orcid.org/0000000188938471
700    1_
$a Lacerenza, Serena $u Institute of Biomedicine of Seville (IBiS; US, CSIC, HUVR), Seville, Spain $1 https://orcid.org/0000000324750706
700    1_
$a Mondaza-Hernandez, Jose L $u Research Health Institute of Fundacion Jimenez Diaz (IIS/FJD; UAM), Madrid, Spain $1 https://orcid.org/0000000256423796
700    1_
$a Martin-Ruiz, Marta $u Research Health Institute of Fundacion Jimenez Diaz (IIS/FJD; UAM), Madrid, Spain $1 https://orcid.org/0000000307118979
700    1_
$a Ramirez-Calvo, Marta $u Fundación Institute Valenciano of Oncology, Valencia, Spain $1 https://orcid.org/0000000271795360
700    1_
$a Grignani, Giovanni $u Medical Oncology Unit, Città della Salute e della Scienza di Torino, Turin, Italy $1 https://orcid.org/000000015515569X
700    1_
$a Martinez-Trufero, Javier $u Department of Medical Oncology, University Hospital Miguel Servet, Zaragoza, Spain $1 https://orcid.org/0000000209972573
700    1_
$a Redondo, Andres $u Department of Medical Oncology, University Hospital La Paz, Madrid, Spain $1 https://orcid.org/0000000272575642
700    1_
$a Valverde, Claudia $u Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain $1 https://orcid.org/0000000341078616
700    1_
$a Stacchiotti, Silvia $u Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy $1 https://orcid.org/0000000217428666
700    1_
$a Lopez-Pousa, Antonio $u Department of Medical Oncology, Sant Pau Hospital, Barcelona, Spain $1 https://orcid.org/0000000310663951
700    1_
$a Lopez-Guerrero, José A $u Fundación Institute Valenciano of Oncology, Valencia, Spain $u Joint Cancer Research Unit IVO-CIPF, Valencia, Spain $u Department of Pathology, Medical School of the Catholic University of Valencia, Valencia, Spain $1 https://orcid.org/0000000273698388
700    1_
$a Gutierrez, Antonio $u Department of Hematology, University Hospital Son Espases, Mallorca, Spain $1 https://orcid.org/000000019062077X
700    1_
$a Encinas-Tobajas, Victor $u Department of Radiology, University Hospital Virgen del Rocio, Sevilla, Spain $1 https://orcid.org/0000000287854898
700    1_
$a Hindi, Nadia $u Research Health Institute of Fundacion Jimenez Diaz (IIS/FJD; UAM), Madrid, Spain $u Department of Medical Oncology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain $u University Hospital General de Villalba, Madrid, Spain $1 https://orcid.org/000000025864762X
700    1_
$a Sangiolo, Dario $u Department of Oncology, University of Torino, Turin, Italy $1 https://orcid.org/0000000271637071
700    1_
$a Lopez-Martin, Jose A $u Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain $1 https://orcid.org/0000000175303207
700    1_
$a Strizova, Zuzana Ozaniak $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000349769534 $7 hka20191025149
700    1_
$a Martin-Broto, Javier $u Research Health Institute of Fundacion Jimenez Diaz (IIS/FJD; UAM), Madrid, Spain $u Department of Medical Oncology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain $u University Hospital General de Villalba, Madrid, Spain $1 https://orcid.org/0000000173506916
773    0_
$w MED00001121 $t Clinical cancer research $x 1557-3265 $g Roč. 30, č. 22 (2024), s. 5192-5206
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39283727 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104339 $b ABA008
999    __
$a ok $b bmc $g 2263307 $s 1239463
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 30 $c 22 $d 5192-5206 $e 20241115 $i 1557-3265 $m Clinical cancer research $n Clin Cancer Res $x MED00001121
GRA    __
$p Sarcoma Foundation of America (SFA)
GRA    __
$a NA $p Asociacion Iker
GRA    __
$a GEIS-52 $p Spanish group for research on Sarcoma
GRA    __
$a GA UK No. 94323 $p Charles University
GRA    __
$a AZV NU23J-08-00031 $p Ministry of Health, Czech Republic
GRA    __
$a 825806 $p Horizon 2020 Framework Programme (H2020)
GRA    __
$a CD20/00155 $p Instituto de Salud Carlos III (ISCIII)
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace